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pharmacological stabilization was found to prevent both 
the structural and functional deficits caused by tau hyper-
phosphorylation. Finally, we demonstrate that the AIS of 
neurons from tau transgenic mice is further down the axon, 
which correlates with a reduction in excitability. We there-
fore propose that a reduction in hippocampal excitabil-
ity due to a tau-mediated distal relocalization of the AIS 
contributes to the hippocampal dysfunction observed in 
tauopathies.
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Introduction
The intracellular accumulation of the microtubule-asso-
ciated protein tau in a hyperphosphorylated form char-
acterizes many neurodegenerative diseases, including 
Alzheimer’s disease (AD) and major forms of fronto-
temporal lobar degeneration (FTLD-Tau) [23]. Although 
tau accumulation is central to these diseases, the mecha-
nism whereby pathological tau impairs neuronal func-
tion is incompletely understood. To address this issue, 
a range of transgenic animal models have been gener-
ated that express different mutant forms of tau found in 
familial cases of FTLD-Tau [12, 15, 22]. Expression of 
these forms of tau recapitulates major aspects of the 
human pathology, including hyperphosphorylation, neu-
rofibrillary tangle (NFT) formation, neurodegeneration 
and impaired hippocampal-dependent spatial memory, as 
demonstrated by the rTg4510 mouse strain that expresses 
the human P301L mutation of FTLD-Tau [21, 31, 36, 
40, 45]. Furthermore, using the rTg4510 mouse model, 
it has been shown that the early stage of tau aggregation 
Abstract Hyperphosphorylated tau has a critical role in 
tauopathies such as Alzheimer’s disease and frontotem-
poral dementia, impairing neuronal function and eventu-
ally leading to neurodegeneration. A critical role for tau 
is supported by studies in transgenic mouse models that 
express the P301L tau mutation found in cases of familial 
frontotemporal dementia, with the accumulation of hyper-
phosphorylated tau in the hippocampus causing reduc-
tions in hippocampal long-term potentiation and impair-
ments in spatial learning and memory. However, what has 
remained unexplored is the role of hyperphosphorylated 
tau in reducing neuronal excitability. Here, we show in 
two complementary P301L tau transgenic mouse models 
that hyperphosphorylated tau induces a more depolarized 
threshold for action potential initiation and reduces firing in 
hippocampal CA1 neurons, which was rescued by the sup-
pression of transgenic tau. Furthermore, using mutagenesis 
and primary hippocampal neuronal cultures, we reveal that 
this reduction in neuronal excitability results from the relo-
cation of the axon initial segment (AIS) down the axon in 
a tau phosphorylation-dependent manner. We also demon-
strate that this effect is microtubule-dependent. In addition, 
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and hyperphosphorylation which precedes NFT forma-
tion strongly correlates with neuronal dysfunction [2–4, 
31, 43, 45]. To identify how this occurs, numerous studies 
have focussed on the involvement of tau impaired synap-
tic activity [5, 21, 24, 29]. However, its impact on neu-
ronal excitability has received less attention, although it 
has been reported that the removal of tau reduces network 
hyperexcitability [7, 20, 42], suggesting an important role 
in the modulation of neuronal excitability. Here, we used 
patch-clamp electrophysiology of hippocampal CA1 neu-
rons in two tau pathology mouse models, the rTg4510 
strain and a second model, pR5, that also expresses P301L 
mutant Tau, albeit at much lower levels [14]. Electrophys-
iological recordings in brain slices were complemented 
by an analysis of primary hippocampal neurons that were 
transfected with different forms of tau, both mimick-
ing and abrogating hyperphosphorylation, to determine 
if hyperphosphorylated tau reduces neuronal excitabil-
ity. CA1 hippocampal rather than cortical neurons were 
investigated as previous reports have revealed a role for 
hyperphosphorylated tau in impairing hippocampus-
dependent memory functions in animal studies [21, 37, 
40]. This allowed us to identify a critical role for hyper-
phosphorylated tau in impairing hippocampal neuronal 
excitability by distally relocating the axon initial segment 
(AIS) in a microtubule-dependent manner that preceded 
neurodegeneration.
Methods
Ethics statement and mouse strains
All experimental procedures were conducted under the 
guidelines of the Australian Code of Practice for the 
Care and Use of Animals for Scientific Purposes and 
were approved by the University of Queensland Animal 
Ethics Committee (QBI/412/14/NHMRC; QBI/027/12/
NHMRC). Experiments and data analysis were performed 
blind to the experimental group. Mice were maintained 
on a 12-h light/dark cycle and housed in a PC2 facility 
with ad libitum access to food and water. In addition to 
wild-type mice, two P301L mutant human tau trans-
genic mouse strains were used: the inducible rTg4510 
strain that is characterized by a 13-fold overexpression of 
human tau compared to endogenous tau [45], and the pR5 
strain that expresses human tau at approximately 70% of 
the levels of endogenous mouse tau [13]. Male and female 
mice were used at an equal ratio and were randomly allo-
cated to experimental groups. To suppress transgenic tau 
expression, rTg4510 mice were fed ad libitum a chow diet 
containing doxycycline (625 mg/kg) for 4 weeks, as pre-
viously described [45].
Brain slice preparation
Acute brain slices were prepared similar to previous reports 
[18, 35]. rTg4510 [45], pR5 [14] and wild-type control 
mice were anesthetized with 2% isoflurane (Attane) and 
transcardially perfused with cold cutting solution compris-
ing (in mM) 125 choline-Cl, 2.5 KCl, 0.4 CaCl2, 6 MgCl2, 
1.25 NaH2PO4, 26 NaHCO3 and 20 d-glucose saturated 
with 95% O2 and 5% CO2. The mice were then decapitated 
and the brain quickly removed. 300 µm coronal hippocam-
pal brain slices were cut on a vibratome (VT1000S, Leica). 
Slices were rested for 30 min at 35 °C and then at room 
temperature (RT) for at least 30 min prior to electrophysi-
ological recordings.
Whole‑cell patch‑clamp electrophysiology
Slices were transferred to a submerged recording chamber 
on an upright microscope (Slicescope Pro 1000; Scienti-
fica) and perfused with an oxygenated recording artificial 
cerebrospinal fluid solution comprising (in mM) 125 NaCl, 
2.5 KCl, 2 CaCl2, 2 MgCl2, 1.25 NaH2PO4, 26 NaHCO3, 
10 d-glucose at 32 °C. CA1 neurons were identified visu-
ally, using infrared-oblique illumination microscopy with 
a 40× water-immersion objective (Olympus) and a CCD 
camera (Jenoptik, Optical Systems GmbH) as well as by 
their action potential (AP) firing characteristics: pyrami-
dal neurons were found in the stratum pyramidale of the 
CA1 region and displayed AP firing that was accommo-
dating at high current injections and had a wide AP (see 
Fig. 1) [34, 48], whereas fast-spiking inhibitory interneu-
rons were found in the stratum oriens of the CA1 region 
and fired non-accommodating AP trains at high stimulation 
currents with a narrow AP width (see Supplementary Fig-
ure 3) [11, 27, 49]. Transfected hippocampal primary neu-
ron cultures were perfused with a HEPES-buffered external 
solution composed of (in mM) 140 NaCl, 5 KCl, 2 CaCl2, 1 
MgCl2, 10 HEPES, and 10 d-glucose (pH 7.4) at 25 °C and 
were identified based on enhanced green fluorescent pro-
tein (EGFP) expression. Whole-cell patch-clamp record-
ings were performed using a micro-manipulator (Scienti-
fica) and an Axon MultiClamp 700B patch-clamp amplifier 
(Molecular Devices). Data were acquired using pClamp 
software (v10; MDS) with a sampling rate of 50 kHz after 
Bessel filtering at 10 kHz (Digidata 1440a; Axon). Patch 
pipettes (4–7 MΩ; GC150F-10; Harvard Instruments) were 
pulled using a micropipette puller (PC-10; Narishige) and 
then filled with an internal solution containing (in mM) 125 
K-gluconate, 5 KCl, 2 MgCl2·6H20, 10 HEPES, 4 ATP-Mg, 
0.3 GTP-Na, 10 phosphocreatine, 10 EGTA and 0.2% bio-
cytin (pH 7.24 and 291 mOsm). Neuronal capacitance and 
input resistance were determined in voltage-clamp mode 
with the cells being held at −70 mV for neurons from 
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brain slices and −60 mV for primary cultures. Neuronal 
excitability was determined in current-clamp mode, with a 
holding current injected to maintain the membrane poten-
tial at approximately −70 mV for neurons in brain slices 
and −60 mV for primary cultures. Current steps were then 
injected to generate AP firing.
Electrophysiology data analysis
Data were analyzed using the Axograph X software. Indi-
vidual APs were identified using a 50 mV/ms threshold 
for neurons from brain slices and 10 mV/ms for primary 
cultured neurons. Raw traces were normalized by baseline 
subtraction. Input–output relationships were calculated by 
determining the number of APs that were generated for 
each injected current step. The integrated AP firing, which 
was used to compare AP firing between groups, was cal-
culated from the area underneath individual input–output 
relationships for all current steps. All analysis of AP mor-
phology was calculated from the first AP fired. The thresh-
old for AP firing was determined, prior to baseline sub-
traction, at the membrane potential at which the threshold 
was reached. The rheobase current was determined as the 
first current step from which an AP was generated. The AP 
amplitude and after hyperpolarization (AHP) were calcu-
lated relative to threshold. The AP rise-time was calculated 
Fig. 1  Neuronal excitability is reduced in rTg4510 and pR5 CA1 
pyramidal neurons. a Representative traces of APs fired by rTg4510 
(red), pR5 (green) and wild-type (black) neurons following injection 
of a −60, 0, rheobase and 320 pA current step. b Input–output rela-
tionships from rT4510 mice aged 1–2 months (top row), 4–6 months 
(second row), and 12–14 months (third row) as well as pR5 mice 
aged 15–17 months (fourth row) and wild-type age-matched con-
trol neurons (top row rTg4510 n = 16 neurons n = 5 mice, wild-
type n = 16 neurons n = 3 mice, p = 0.0004; second row rTg4510 
n = 24 neurons n = 4 mice, wild-type n = 26 neurons n = 4 mice, 
p = 0.0124; third row rTg4510 n = 12 neurons n = 5 mice, wild-
type n = 20 neurons n = 4 mice, p = 0.0003; fourth row pR5 n = 9 
neurons n = 3 mice, wild-type n = 11 neurons n = 3 mice, p = 0.15). 
c Representative traces of the first APs fired in rT4510 and wild-type 
control neurons. Pooled data demonstrating the AP firing of neurons 
from transgenic tau neurons compared to wild-type controls, includ-
ing d AP threshold (top row p = 0.0148; second row p = 0.0044; 
third row p = 0.0002; fourth row p = 0.0313), (e) AP amplitude 
(top row p = 0.0147; second row p = 0.0188; third row p = 0.0002; 
fourth row p = 0.0499), and f rheobase (top row p = 0.0008; second 
row p = 0.0124; third row p = 0.90; fourth row p = 0.23). *p < 0.05, 
**p < 0.01, ***p < 0.001. Data presented as mean ± SEM and indi-
vidual data points. Statistical comparisons were made using an 
unpaired two-tailed Student’s t test
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as the time between 10 and 90% of the maximal AP ampli-
tude. The AP half-width was determined at 50% of the 
maximal AP amplitude. The sag potential was calculated 
by subtracting the membrane voltage at the beginning of 
a −60 pA, 400 ms hyperpolarizing current step from the 
steady state [35].
Neuron recovery, brain slice immunohistochemistry 
and tracing and analysis of dendritic tree morphology
Following electrophysiological recordings, slices were 
fixed in cold 4% paraformaldehyde overnight and then 
washed three times for 10 min with a 1× Tris-buffered 
saline (TBS) solution. They were then incubated for 1 h in 
a blocking solution containing 3% bovine serum albumin 
(BSA), 50 µM glycine, 0.05% sodium azide, and 0.3% Tri-
ton X-100 in TBS at RT. Following three 10 min washes 
with TBS, slices were incubated with the mouse AT180 
antibody (reactive with tau phosphorylated at Thr231/
Ser235; 1:2000; Thermo Scientific) in a solution containing 
of 0.5% BSA, 0.05% sodium azide, and 0.1% Triton X-100 
in TBS for 48 h at RT. After primary antibody incubation, 
the slices were washed three times for 10 min with TBS 
and incubated in a secondary solution containing Streptavi-
din coupled to AlexaFluor 594 (1:2000; Life Technologies), 
goat anti-mouse immunoglobulin G coupled to AlexaFluor 
488 (1:2000; Life Technologies), 0.1% Triton X-100, and 
0.05% sodium azide in TBS overnight at RT. After a final 
three washes with TBS, slices were cover-slipped with 
Vectashield mounting medium (H-1400; Vector Laborato-
ries Inc.) and stored at 4 °C.
The dendritic morphology of patched neurons was 
imaged using a confocal microscope (LSM710; Zeiss) 
equipped with a 20× air objective (0.8 NA; Zeiss). All 
images were acquired using Zen 2012 software (Zeiss). 
Recovered neurons were manually traced using Neurolu-
cida software (MBF Bioscience). Neuroexplorer software 
(MBF Bioscience) Branch Analysis was used to calculate 
dendritic length and the number of branch nodes.
Determining CA1 neuronal densities
Whole brains of rTg4510 and wild-type mice were fixed 
in cold 4% paraformaldehyde overnight, after which they 
were washed three times for 10 min with PBS solution. 
Sections (50 µm) were then prepared using a vibratome 
(Leica). Brain slices were incubated for 1 h in a blocking 
solution containing 0.5% BSA, 0.1% Triton X-100, and 
0.05% sodium azide in PBS at RT. The slices were then 
incubated with mouse anti-NeuN antibody (1:500; Mil-
lipore) in blocking solution for 48 h at RT, after which 
they were washed again three times for 10 min with PBS 
and incubated in a secondary solution containing goat 
anti-mouse IgG coupled to AlexaFluor 488 (1:500; Life 
Technologies) in blocking solution for 3 h at RT. After a 
final three washes with PBS, the slices were cover-slipped 
with Vectashield mounting medium (H-1400; Vector Labo-
ratories Inc.) and stored at 4 °C. To calculate CA1 neuronal 
densities the brain slices were imaged using a spinning-
disk confocal system (Marianas; 3I, Inc.) consisting of an 
Axio Observer Z1 (Zeiss) equipped with a CSU-W1 spin-
ning-disk head (Yokogawa Corporation of America) and an 
ORCA-Flash4.0 v2 sCMOS camera (Hamamatsu Photon-
ics) with a 40× oil-immersion objective (1.4 NA; Zeiss).
Tau expression constructs
All human tau constructs were expressed the 441-amino 
acid (2N4R) isoform of human tau carboxy-terminally 
tagged with EGFP (referred to as Tau-EGFP) in the EGFP-
N1 vector (Clontech) under the control of the CMV pro-
moter. Two mutant Tau-EGFP constructs termed E14 and 
A14 (all 14 serine or threonine residues T111, T153, T175, 
T181, S199, S202, T205, T212, T217, T231, S235, S396, 
S404, and S422 mutated to glutamic acid (E14) or alanine 
(A14), respectively) were generated by subcloning the 
mutant Tau fragment from pRK5-EGFP-Tau E14 (0N4R 
Tau, Addgene plasmid # 46907) or pRK5-EGFP-Tau AP 
(0N4R Tau, Addgene plasmid # 46905) into the wild-type 
Tau-EGFP backbone, using the Gibson assembly method 
(NEB E5510S). Generation of the AT180, 12E8 and PHF1 
mutant tau constructs has been described previously [52]. 
Sanger sequencing was employed to confirm all construct 
sequences.
Primary hippocampal neuron culture, 
immunocytochemistry and axon initial segment 
imaging and quantification
Hippocampal neurons from embryonic day 17 (E17) 
C57BL/6 mouse embryos were dissected and plated onto 
poly-d-lysine-coated coverslips in a 12-well plate at a den-
sity of 70,000 cells/well [9]. The plating medium was based 
on Neurobasal medium (Invitrogen), supplemented with 
5% fetal bovine serum (Hyclone), 2% B27 (Gibco), 2 mM 
Glutamax (Invitrogen) and 50 U/ml penicillin/streptomycin 
(Invitrogen). This was changed to serum-free Neurobasal 
medium 24 h post-seeding, after which half of the medium 
was changed every three days. Neurons were transfected 
at 14 days in vitro (DIV 14) using Lipofectamine 2000 
(Invitrogen) for either 24 or 48 h. With respect to micro-
tubule stabilizing/destabilizing experiments, taxol (0.1 µM, 
Sigma) and nocodazole (0.05 µM, Sigma) were added 
when changing the transfection medium.
Following transfections, cells were fixed for 10 min 
with 4% paraformaldehyde for ankyrin G staining or 1% 
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paraformaldehyde for NaV1.6 and βIV spectrin co-stain-
ing with ankyrin G. Following three 15-min washes with 
PBS, the cells were permeabilized in 0.25% Triton X-100 
for 10 min at RT, blocked in 0.5% BSA in PBS for 1 h, 
and incubated overnight at RT with 0.5% BSA in PBS with 
one of three primary antibody configurations: (1) rabbit 
anti-ankyrin G (1:500, Santa Cruz) and mouse anti-NaV1.6 
(1:200, NeuroMab); (2) rabbit anti-ankyrin G (1:500) and 
goat anti-βIV spectrin (1:200, Santa Cruz), or (3) rabbit 
anti-ankyrin G (1:500).
The co-staining of ßIV spectrin or NaV1.6 with ankyrin 
G was performed to confirm AIS localization. The cells 
were then washed three times for 15 min and incubated in a 
secondary antibody solution composed of AlexaFluor-594 
(1:500, Invitrogen) for single antibody staining or Alex-
aFluor-594 and AlexaFluor-647 (1:500, Invitrogen) for dual 
staining and 0.5% BSA in PBS for 1 h at RT. Following 
a final three 15-min washes in PBS, cells were mounted 
using Vectashield mounting medium (H-1000; Vector Lab-
oratories Inc.) and stored at 4 °C.
The AIS of stained hippocampal primary culture neu-
rons was imaged using confocal microscopy (LSM710; 
Zeiss), using a 63× oil-immersion lens (1.4 NA; Zeiss), 2× 
digital zoom and Nyquist sampling so that each image was 
acquired with 16 bits per pixel and an individual pixel reso-
lution of 0.0375 × 0.0375 × 0.13 µm3. Images were decon-
volved using Huygens Professional software (SVI). The 
quantification of the AIS location and length was performed 
using z-stack images flattened into a single maximal pro-
jection using NIH Image J (http://www.imagej.nih.gov/
ij/) and imported into MATLAB (Mathworks) for analysis 
using previously published custom-written functions (Mat-
thew Grubb and Thomas Watkins, King’s College London, 
London, UK [8, 16]; obtained from www.mathworks.com/
matlabcentral/fileexchange/28181-ais-quantification). The 
start and end points were calculated as the point along the 
axon where the normalized fluorescence intensity increased 
above one-third of maximal, and the mid-point was calcu-
lated as the halfway point between the identified start and 
end. The integrated fluorescence intensity was calculated as 
the area underneath the profile between the identified start 
and end positions using a custom MATLAB script. Axonal 
A14 and E14 expression levels were analyzed by convert-
ing 16-bit images to an 8-bit image and determining the 
mean gray value intensity of the axon, with the background 
mean gray value subtracted from the axonal intensity.
AIS localization from whole‑cell patch‑clamp recorded 
neurons
Following electrophysiological recordings, slices were 
fixed in cold 4% paraformaldehyde overnight, washed 
three times for 10 min with a 1x PBS solution and 
incubated for 1 h in a blocking solution containing 3% 
bovine serum albumin (BSA), 50 µM glycine, 0.05% 
sodium azide, and 0.3% Triton X-100 in PBS at RT. Fol-
lowing three 10-min washes with PBS, the slices were 
incubated with Streptavidin coupled to AlexaFluor 594 
(1:2000; Life Technologies) with 0.1% Triton X-100, 
and 0.05% sodium azide in PBS for 48 h at RT. After 
a further three 10-min washes with PBS, the slices 
were cover-slipped with Vectashield mounting medium 
(H-1400; Vector Laboratories Inc.) and imaged using 
spinning-disk confocal microscopy (20x air objective, 
NA 1.4) to identify the recorded neurons. Once identi-
fied, the coverslips were removed and the slices were 
sub-sectioned to a thickness of 80 µm and, following 
three 10-min washes with PBS, incubated with a rab-
bit anti-ankyrin G (1:500) antibody in a solution con-
taining of 0.5% BSA, 0.05% sodium azide, and 0.1% 
Triton X-100 in PBS for 48 h at RT. Following the pri-
mary antibody incubation, the slices were washed three 
times for 10 min with PBS and incubated in a second-
ary solution containing Streptavidin coupled to Alex-
aFluor 594 (1:2000; Life Technologies) and donkey 
anti-rabbit immunoglobulin G coupled to AlexaFluor 
488 (1:2000; Life Technologies), 0.1% Triton X-100, 
and 0.05% sodium azide in PBS overnight at RT. After 
a final three washes with PBS, slices were cover-slipped 
with Vectashield mounting medium (H-1400; Vector 
Laboratories Inc.) and stored at 4 °C. Neurons were then 
imaged using spinning-disk confocal (63× oil-immer-
sion objective NA 1.4) with Nyquist sampling that ena-
bled a voxel resolution of 0.0992 × 0.0992 × 0.130 µm3 
(XYZ). Images were deconvolved using Huygen’s Pro-
fession software. The start of the AIS of the recorded 
neurons was determined using z-stack images flattened 
into a single maximal projection image using NIH Image 
J and imported into MATLAB for analysis using a pre-
viously published custom-written function, as was pre-
viously performed to determine the AIS location in pri-
mary cultured neurons.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
software (v6; GraphPad Software Inc.). Statistical compari-
sons between groups were made using an unpaired two-tailed 
Student’s t test. A one-way ANOVA with a Sidak’s post hoc 
test was used for multiple comparisons. A linear regression 
analysis was performed to determine the relationship between 
AIS location and neuronal activity with r2 values reported. An 
alpha value of 0.05 was used in all cases. Data are presented 




Depolarized action potential initiation and reduced 
firing in CA1 neurons of two P301L tau transgenic 
mouse models
To investigate if AP firing was impaired in the hippocam-
pal CA1 region of FTLD-Tau mutant P301L tau transgenic 
mice, we first performed whole-cell patch-clamp record-
ings from rTg4510 and wild-type mice aged 1–2 months 
(an early stage of tauopathy prior to overt tau hyperphos-
phorylation and synaptic impairment), 4–6 months (a 
mid-stage with extensive tau hyperphosphorylation and 
impairment of synaptic activity and spatial memory) and 
12–14 months (a late stage after synaptic loss and neuro-
degeneration have been initiated) [21, 41, 45]. At all ages 
investigated, AP firing was reduced in rTg4510 excitatory 
pyramidal neurons compared to the wild-type controls 
(Fig. 1a, b). Consistent with this observation, the thresh-
old for AP firing was shifted in a depolarized direction 
and the AP amplitude was reduced in all rTg4510 neu-
rons (Fig. 1c–e), indicating that the reduction in CA1 AP 
firing was due to a depolarized shift in the threshold for 
AP initiation. In addition to these changes, the rheobase 
current required to fire the initial AP was increased in 
rTg4510 neurons at 1–2 and 4–6 months of age, but not at 
12–14 months (Fig. 1f), which may result from an increase 
in input resistance that was only observed at this time point 
(Supplementary Figure 1a–c). The AP rise-time and half-
width were only reduced at 1–2 months of age and not in 
the older age groups, and the AHP and holding current of 
rTg4510 neurons were only enhanced from 4 to 6 months 
onwards compared to that of wild-type neurons (Supple-
mentary Figure 2a–d), suggesting that these changes were 
not the cause of the reduced AP firing. Unlike what has 
been reported in layer 3 cortical neurons of rTg4510 mice 
[3], the sag potential was not altered at any age in CA1 
pyramidal neurons (Supplementary Figure 2e). Taken 
together, these data demonstrate that the AP firing of CA1 
neurons is consistently impaired in the rTg4510 mouse 
model due to a depolarizing shift in AP initiation.
Although the P301L tau mutation in the rTg4510 
mouse model is driven by the CaMKII promoter that tar-
gets expression to excitatory neurons, we also performed 
patch-clamp recordings from fast-spiking CA1 inhibi-
tory interneurons to determine if their excitability was 
altered. However, other than a reduction in AP rise-time at 
12–14 months of age, no change in rTg4510 AP firing, AP 
morphology or passive properties was observed compared 
to wild-type controls at any age investigated (Supplemen-
tary Figure 1d–f; Supplementary Figure 3), indicating that 
excitatory but not inhibitory neuronal function is impaired 
in rTg4510 mice.
Whereas the rTg4510 mouse model faithfully recapitu-
lates many aspects of human tauopathies, one potential 
limitation is the high expression level of P301L human tau, 
which is 13-fold higher than that of endogenous tau [45]. 
We therefore investigated if CA1 pyramidal neuron AP fir-
ing was also impaired in the pR5 mouse model, which har-
bors the same mutation but expresses mutant human tau at 
much lower levels, 0.7 times those of endogenous murine 
tau [14]. Reflecting these lower levels, tau pathology in the 
pR5 mice develops later and is less pronounced than that in 
the rTg4510 strain. For example, whereas NFT formation 
in pR5 mice is initiated in the amygdala at 6 months and 
eventually spreads to the hippocampus, in rTg4510 mice 
these lesions are already detectable throughout the brain at 
2.5 months of age [6, 14, 41, 45]. Despite this difference 
in pathology, patch-clamp recordings from CA1 pyramidal 
neurons in brain slices from 15- to 17-month-old pR5 mice 
revealed a similar, although less severe AP impairment to 
that observed in the rTg4510 model. Although AP firing 
was not significantly reduced in pR5 neurons (Fig. 1a, b), 
the AP threshold was shifted in a depolarized direction and 
the AP amplitude was reduced compared to wild-type litter-
mates, consistent with the above recordings from rTg4510 
mice (Fig. 1c–e). No changes in the rheobase, AP rise-time, 
AP half-width, sag potential, holding current, neuronal 
capacitance or input resistance were observed, whereas the 
AHP amplitude was increased in pR5 neurons compared 
to wild-type controls (Fig. 1f; Supplementary Figure 1g; 
Supplementary Figure 2a–e). This demonstrates that, as for 
rTg4510 CA1 neurons, the threshold for AP initiation is 
shifted in a depolarized direction in the pR5 strain.
Reduced firing in rTg4510 mice occurs in the presence 
of hyperphosphorylated tau prior to neurodegeneration
rTg4510 mice are characterized by the neuronal accumu-
lation of hyperphosphorylated tau that eventually leads to 
neurodegeneration, which is clearly apparent by 5.5 months 
of age [1], whereas neuronal loss has not been reported in 
the pR5 model [14]. We therefore used the rTg4510 mouse 
model to investigate if neurodegeneration was causing the 
observed reduction in AP firing. We first determined the 
tau pathology in brain slices from rTg4510 and wild-type 
mice at the ages at which we had recorded. Strong immu-
noreactivity for hyperphosphorylated tau, as shown for 
the early pathological phospho-epitope AT180 (pThr231/
pSer235), was observed in the CA1 pyramidal neuron layer 
of rTg4510 mice at all ages examined, but was absent in 
wild-type controls (Fig. 2a). The presence of tau hyper-
phosphorylation in the CA1 region of pR5 mice has pre-
viously been demonstrated [6, 50]. Furthermore, immuno-
reactivity for hyperphosphorylated tau was observed prior 
to changes in CA1 neuronal density (Fig. 2b, c), indicating 
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that tau hyperphosphorylation and neuronal dysfunction 
occur before cell loss. To determine if this presence of 
hyperphosphorylated tau was causative in the reduction 
of neuronal excitability observed in the rTg4510 mouse 
model, we treated rTg4510 mice with doxycycline to sup-
press expression of the tau transgene [45]. Patch-clamp 
recordings revealed that feeding rTg4510 mice doxycycline 
for a period of four weeks was sufficient to completely 
reverse the impairments observed in control rTg4510 mice 
(Fig. 2d–g). We next assessed the dendritic morphology 
of the CA1 pyramidal neurons from control rTg4510 and 
wild-type mice from which we had recorded. We observed 
no change in the length or number of branch nodes in either 
the apical or basal tree of 1- to 2- and 4- to 6-month-old 
rTg4510 neurons compared to wild type (Fig. 3a–f). How-
ever, by 12–14 months of age an extensive reduction in 
dendritic length and complexity was observed (Fig. 3a–f). 
Together, these data indicate that the reduction in AP firing 
of CA1 pyramidal neurons is caused by the presence of 
hyperphosphorylated tau and is not a consequence of 
neurodegeneration.
Pseudo‑hyperphosphorylated tau relocates the AIS 
down the axon
AP initiation occurs at the AIS [39], facilitated by the 
high concentration of voltage-gated sodium (NaV) chan-
nels [10, 28, 44]. NaV channel localization to the AIS is 
achieved through the interaction of ion channels with the 
AIS-specific cytoskeletal protein ankyrin G [25, 55], a 
commonly used AIS marker. One mechanism by which the 
AIS tunes neuronal excitability is by changing its location 
along the axon in an activity-dependent manner, such that 
an increase in the distance of the AIS from the soma results 
in reduced neuronal excitability [16]. Considering that, in 
tau-overexpression systems, fluorescence intensity profiles 
Fig. 2  Early hyperphosphorylated tau visualized in brain slices from 
rTg4510 mice. a Representative photomicrographs demonstrating 
AT180 (pThr231/pSer235) staining in brain slices from rTg4510 (top 
row) and wild-type (bottom row) mice at 1–2 (left), 4–6 (middle) and 
12–14 months of age (right). Scale bar 50 µm. b Representative pho-
tomicrographs of NeuN staining of rTg4510 (top row) and wild-type 
(bottom row) CA1 neurons in 2-month-old mice. Scale bar 10 µm. 
c Quantification of neuronal density in the CA1 region (p = 0.25, 
n = 3 mice per group). d Input–output relationship (rTg4510 doxy-
cycline n = 14 neurons n = 3 mice, rTg4510 control n = 14 neurons 
n = 3 mice, p = 0.0102). e AP threshold (p = 0.0025), f AP ampli-
tude (p = 0.0329) and g rheobase current (p < 0.0001) for rTg4510 
mice fed a doxycycline-containing chow diet or control diet for 
4 weeks: rTg4510 mice where 3 months of age at the beginning of 
the treatment. *p < 0.05, **p < 0.01, ***p < 0.001. Data presented 
as mean ± SEM and individual data points. Statistical comparisons 
were made using an unpaired two-tailed Student’s t test
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have revealed that the highest levels of tau are in the proxi-
mal axon where the AIS is located [51], we asked whether 
the presence of hyperphosphorylated tau could change the 
location of the AIS relative to the soma, which would then 
affect the firing properties of the neuron.
To address this, we transfected primary hippocam-
pal neurons with either an E14 tau expression construct 
(with 14 critical Ser/Thr residues being replaced by glu-
tamic acid) to mimic tau hyperphosphorylation, or a cor-
responding A14 control construct (where these residues 
were replaced by alanine) to prevent phosphorylation 
[21]. Both of these constructs were carboxy-terminally 
tagged with EGFP to facilitate the identification of trans-
fected neurons. Interestingly, 48 h after transfection, the 
entire AIS of the E14-expressing neurons was relocated 
approximately 4–5 µm down the axon without altering the 
AIS length compared to A14-expressing controls, as deter-
mined by analysis of the ankyrin G fluorescence profile 
(Fig. 4b, d, f; Supplementary Figure 4b). In contrast, at the 
earlier time-point of 24 h post-transfection, no change in 
the location or length of the AIS was observed (Fig. 4a, c, 
e; Supplementary Figure 4a). As there was no difference 
in the expression levels of E14- and A14-tau in the axons 
of transfected neurons (Supplementary Data Figure 5a, b), 
and the location and length of the AIS were not different in 
A14-expressing neurons compared to GFP-transfected cells 
(Supplementary Figure 4c, d), we concluded that hyper-
phosphorylation of tau, and not simply its overexpression, 
had induced the relocation of the AIS. To determine if the 
entire AIS was relocated rather than just one of its struc-
tural elements, we next investigated the location of two 
additional AIS-specific proteins: the scaffolding protein 
ßIV spectrin and the NaV1.6 subunit, which is critical for 
AP initiation [44, 53]. Importantly, as for ankyrin G, both 
proteins were shifted to the same extent down the axons 
of E14-expressing neurons compared to A14-expressing 
controls (Fig. 4g, h), without altering the AIS length (Sup-
plementary Fig. 4e, f). This shift in AIS position was not 
accompanied by a change in the protein level of ankyrin 
G, ßIV spectrin or NaV1.6 as determined by immunocyto-
chemistry (Supplementary Figure 5c–e).
We next expressed phosphorylation-mimicking (E) and 
phosphorylation-abrogating (A) mutant forms of three tau 
epitopes that are known to be hyperphosphorylated in AD, 
AT180 (pThr231/pSer235), 12E8 (pSer262/pSer356) and 
PHF1 (pSer396/pSer404). Transfection with the AT180E 
and 12E8E mutants was sufficient to relocate the AIS down 
the axon, again without altering its length, using AT180A 
and 12E8A transfectants as controls (Fig. 4i, j; Supplemen-
tary Figure 4g), whereas the PHF1E mutant did not alter the 
location or length of the AIS compared to PHF1A (Fig. 4k; 
Supplementary Figure 4g). These results demonstrate that 
Fig. 3  CA1 pyramidal neuron neurodegeneration occurs late in 
rTg4510 mice. Representative 2D projections of 3D reconstructions 
of a rTg4510 and b wild-type neurons at 1–2 (left), 4–6 (middle) and 
12–14 months of age (right). c Total length (1–2 months: rTg4510 
n = 10, wild-type n = 9, p = 0.58; 4–6 months: rTg4510 n = 12, 
wild-type n = 11, p = 0.42; 12–14 months: rTg4510 n = 9, wild-type 
n = 17, p = 0.0228) and d number of branch nodes (1–2 months: 
p = 0.93, 4–6 months: p = 0.24, 12–14 months: p = 0.08) within 
the CA1 pyramidal neuron apical dendritic tree, and e total length 
(1–2 months: p = 0.42, 4–6 months: p = 0.82, 12–14 months: 
p = 0.0001) and f number of branch nodes (1–2 months: p = 0.17, 
4–6 months: p = 0.90, 12–14 months: p = 0.0212) from the basal 
dendritic trees of wild-type and rTg4510 neurons. *p < 0.05. Data 
presented as mean ± SEM and individual data points. Scale bar 
100 µm. Statistical comparisons were made using an unpaired two-
tailed Student’s t test
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Fig. 4  Pseudo-phosphorylated tau relocates the AIS down the axon 
in a process mediated by microtubules. Representative photomi-
crograph of A14- (top) and E14-tau-EGFP (lower) transfected hip-
pocampal neurons stained for ankyrin G a 24 h and b 48 h after 
transfection. Arrows indicate the start, middle and end of the AIS as 
determined by quantitative analysis of the c, d axonal fluorescence 
profile. The dashed line indicates the normalized detection thresh-
old. Quantification of ankyrin G labeling in neurons transfected with 
E14- (blue) and A14-tau (black) for e 24 h (start p = 0.48, middle 
p = 0.94, end p = 0.54; E14 n = 61, A14 n = 46) and f 48 h (start 
p = 0.0001, middle p = 0.0027, end p = 0.0017; E14 n = 47, A14 
n = 62). AIS location of E14- and A14-tau-transfected neurons 
labeled for g βIV spectrin (start p = 0.0041, middle p = 0.0024, 
end p = 0.0084; E14 n = 55, A14 n = 52) and h NaV1.6 (start 
p = 0.0042, middle p = 0.0045, end p = 0.0316; E14 n = 53, A14 
n = 53). Using ankyrin G staining, the role of site-specific phospho-
rylation in AIS relocation was determined: i AT180 (start p = 0.0138, 
middle p = 0.44, end p = 0.76; AT180E n = 53, AT180A n = 52), 
j 12E8 (start p = 0.0183, middle p = 0.0352, end p = 0.09; 12E8E 
n = 54, 12E8A n = 51), and k PFH1 (start p = 0.34, middle 
p = 0.56, end p = 0.75; PHF1E n = 50, PHF1A n = 38). l Treatment 
with 0.1 µM taxol (magenta) prevents AIS relocation (start, ANOVA, 
F = 8.05, p = 0.0005; middle, ANOVA, F = 4.057, p = 0.0191; end, 
ANOVA, F = 6.614, p = 0.0017; E14 n = 57, A14 n = 54, E14+ 
taxol n = 51). m Microtubule destabilization with 0.05 µM noco-
dazole (green) relocates the AIS (gray, control, start: p = 0.0169, 
middle: p = 0.0297, end: p = 0.0856; nocodazole n = 54, control 
n = 55). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p ≤ 0.0001. 
Data presented as mean ± SEM. Scale bar 5 µm. Statistical compari-
sons were made using an unpaired two-tailed Student’s t test or a one-
way ANOVA with a Sidak’s post hoc test
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site-specific phosphorylation at sites such as the Thr231/
Ser235 and Ser262/Ser356 epitopes are involved in the 
relocation of the AIS, whereas a site such as the Ser396/
Ser404 epitope is not critical in this process.
One consequence of the hyperphosphorylation of tau is 
its detachment from microtubules and subsequent micro-
tubule destabilization [47]. To evaluate their role in the 
hyperphosphorylated tau-induced relocation of the AIS, 
we treated E14-expressing neurons with Paclitaxel (taxol) 
to stabilize the microtubules. This treatment prevented the 
relocation of the AIS from its control position (Fig. 4l). 
However, treatment of wild-type EGFP-transfected neurons 
with nocodazole, which pharmacologically destabilizes 
microtubules, caused a distal shift of the AIS (Fig. 4m). 
The AIS length was not altered by either treatment (Sup-
plementary Figure 4h, i). Taken together, these findings 
demonstrate that the hyperphosphorylated tau-mediated 
displacement of the AIS is microtubule-dependent.
Pseudo‑hyperphosphorylated tau reduces firing 
in primary neuronal cultures
We next investigated if the observed distal shift in the 
position of the AIS induced by hyperphosphorylated tau 
alters AP firing by performing whole-cell patch-clamp 
recordings from E14-transfected primary neurons. This 
revealed a similar reduction in neuronal excitability to 
that previously observed in the two tau transgenic mouse 
models, in that both AP firing and the AP amplitude were 
reduced in E14- compared to A14-transfected neurons, 
with a trend for changes in the threshold and rheobase 
(Fig. 5a, b, d–h). Importantly AP firing of untransfected 
neurons was not altered compared to that of A14-express-
ing neurons but was significantly higher than that of 
E14-expressing neurons (Supplementary Figure 6a), 
demonstrating that it is the presence of hyperphosphoryl-
ated tau rather than tau overexpression that impairs neu-
ronal excitability. The AP rise-time and half-width were 
increased in E14-transfected neurons, whereas no change 
was observed in the AHP amplitude, holding current, 
neuronal capacitance and input resistance (Supplemen-
tary Figure 1i; Supplementary Figure 6b–e). No changes 
in the firing and passive properties of E14-transfected 
neurons were observed at 24 h post-transfection com-
pared to A14-transfected controls (Supplementary Fig-
ure 1h; Supplementary Figure 7). In addition, E14-trans-
fected neurons that were treated with taxol to stabilize 
microtubules displayed control levels of AP firing and AP 
amplitude (Fig. 5; Supplementary Figure 6). Although 
the AP threshold, rheobase, rise-time, holding current, 
capacitance and input resistance were not affected by 
taxol treatment, the AP half-width was reduced and the 
AHP amplitude was increased (Fig. 5; Supplementary 
Figure 6). These data suggest that the distal shift in AIS 
Fig. 5  Pseudo-phosphorylated tau reduces AP firing in a similar 
manner to that observed in tau transgenic mouse models. Representa-
tive traces of APs fired by a A14- (black), b E14-transfected (blue) 
neurons and c E14-transfected neurons treated with 0.1 µM taxol 
(magenta) following injection of a −60, 0, rheobase and 320 pA 
current step. d Representative traces of the initial AP fired for A14, 
E14 and E14+ taxol neurons. Pooled data demonstrating the AP fir-
ing, including e input–output relationships (ANOVA, F = 4.084, 
p = 0.0274; E14 n = 12, A14 n = 11, E14+ taxol n = 10), f AP 
threshold (ANOVA, F = 2.439, p = 0.10), g AP amplitude (ANOVA, 
F = 4.152, p = 0.0256), and h rheobase (ANOVA, F = 2.4, 
p = 0.11). *p < 0.05. Data are presented as mean ± SEM and indi-
vidual data points. Statistical comparisons were made using a one-
way ANOVA with a Sidak’s post hoc test between all three groups
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location induced by hyperphosphorylated tau leads to the 
observed reduction in AP initiation and firing, recapitu-
lating the phenotype observed in the two tau transgenic 
mouse models.
The AIS of CA1 pyramidal neurons from rTg4510 
mice are located further down the axon correlating 
with reduced firing
In a final series of experiments, we investigated if this 
distal relocation of the AIS also occurs in CA1 pyramidal 
neurons from 2-month-old rTg4510 mice by performing 
immunohistochemistry on slices in which neurons were 
filled biocytin during whole-cell patch-clamp recordings. 
Similar to the results described in Fig. 1, a reduction in AP 
firing and a depolarization of the threshold for AP firing 
were observed in rTg4510 neurons compared to wild-type 
(Fig. 6a–c). Furthermore, using ankyrin G labeling to iden-
tify the AIS of the filled neurons, we found that the start of 
the AIS of rTg4510 neurons was located further down the 
axon than in wild-type neurons (Fig. 6d, e). A linear rela-
tionship between both AP firing and AP threshold with the 
start of the AIS was observed, with the AIS location being 
negatively correlated with AP firing (Fig. 6f) and positively 
correlated with the threshold for AP initiation (Fig. 6g). 
Collectively, these data indicate that the distal relocation 
of the AIS observed in primary cultures also occurs in tau 
transgenic mice and contributes to the reduction in neu-
ronal firing.
Discussion
In this study, we present a mechanism by which hyper-
phosphorylated tau that accumulates in tauopathies reduces 
neuronal excitability by destabilizing microtubules and 
relocating the AIS, which in turn depolarizes the threshold 
for AP initiation and reduces AP firing (see Fig. 7). The 
causal nature of this relationship is suggested by the rescue 
of the reduced AP firing in rTg4510 mice by suppression 
of pathological tau, and the finding that pharmacological 
stabilization of microtubules prevents both the structural 
and functional deficits induced by hyperphosphorylated 
tau, whereas pharmacological microtubule destabilization 
induces a relocation of the AIS.
An involvement of the AIS in neurodegenerative mod-
els has previously been demonstrated by suggesting that 
it can act as a retrograde barrier to axonal tau that fails in 
the presence of hyperphosphorylated tau and destabilized 
microtubules [33]. It has also been shown very recently 
that tau-mediated destabilization of microtubules includes 
the AIS [46]; however, the primary role of the AIS is in 
the initiation of AP firing, a function that has received lit-
tle attention in neurodegeneration research. Here, we have 
Fig. 6  The AIS of neurons from rTg4510 mice is located further 
down the axon, which correlates with reduced firing and AP threshold 
depolarization. a Representative AP firing of wild-type and rTg4510 
neurons following injection of a −60, 0, rheobase and 320 pA cur-
rent step as well as the quantification of (b) input–output relation-
ship (p = 0.0075, rTg4510 n = 13 neurons n = 3 mice, wild-type 
n = 14 neurons n = 3 mice) and c AP threshold (p = 0.0175). d Rep-
resentative z-projection photomicrographs of AnkG staining (green) 
in biocytin-filled neurons (red) during patch-clamp recordings. 
Arrows indicate the start of the AIS. e Quantification of the start of 
the AIS, determined by fluorescence intensity, in recovered neurons 
(p = 0.0127, rTg4510 n = 4 neurons n = 3 mice, wild-type n = 5 
neurons n = 3 mice). Demonstrates the relationship between the AIS 
location and f AP firing (r2 = 0.45) and g threshold for AP initiation 
(r2 = 0.15). **p < 0.01 and *p < 0.05. Statistical comparisons were 




revealed that hyperphosphorylated tau causes a reduction in 
AP firing by relocating the AIS, with implications for the 
pathogenesis of neurodegenerative diseases such as AD and 
FTLD-Tau. Although we cannot rule out a contribution of 
other changes to AP kinetics, such as AHP amplitude, to the 
reduction in neuronal excitability, these changes were not 
consistent across all models and time points investigated. 
Previous studies that have reported changes in the location 
of the AIS are predominately consistent with the homeo-
static regulation of firing [16, 19, 30]. In contrast, this is 
not the case for the hyperphosphorylated tau-induced relo-
cation of the AIS, which is caused by an intrinsic change 
in the structure of the proximal axon resulting from micro-
tubule destabilization [46]. Interestingly, a recent study 
suggests that a neuron with a more proximally located AIS 
experiences an increased current sink into the large som-
atodendritic region, which reduces the rising phase of an 
AP thereby decreasing its activity [17]. Theoretically, the 
opposite should also apply, a neuron with an AIS located 
distally would experience a reduced current loss from the 
somatodendritic region and, subsequently, increased AIS 
activity; however, this was not experimentally observed 
in the current study. Why this is the case requires further 
investigation, although one possibility could be a change 
in the resistance of the small section of the axon between 
the AIS and the soma, due to changes in the stability of the 
microtubule network.
Altered excitability of cortical neurons, prior to neu-
rodegeneration, has previously been reported in the 
rTg4510 mouse model, although in contrast to our find-
ings an increase in neuronal excitability was observed 
[3, 43]. While this result is yet to be validated in multiple 
tauopathy models, it does suggest that a neuronal dysfunc-
tion resulting from tau hyperphosphorylation occurs in a 
brain region-specific manner. In contrast with these previ-
ous in vitro results yet similar to what we describe here, 
a recent publication reported that pathological tau reduces 
both neocortical single neuron activity and network oscilla-
tions in vivo [36].
The formation of the AIS during development is depend-
ent on intact microtubules [26, 32, 38, 54]. Our data indi-
cate that microtubules also play a role in determining the 
location of the AIS in mature neurons and may provide a 
direct cellular mechanism by which hyperphosphorylated 
tau impairs neuronal activity and possibly contributes to 
deficits in cognitive function. However, further investi-
gation is required to determine how the pathological tau-
mediated reduction in AP firing and previously reported 
impairments in synaptic activity are linked, an important 
step in understanding how pathological tau causes the 
cognitive decline observed in AD. Nonetheless, it is clear 
that pathological tau hyperphosphorylation alters neuronal 
activity well before changes in neuronal morphology and 
density occur.
In addition to the pathological implications, the find-
ings described here provide novel insight into the physi-
ological plasticity of the AIS. Relocation of the AIS has 
previously been reported to occur in an activity-dependent 
Fig. 7  Schematic of major findings. The presence of hyperphospho-
rylated tau destabilizes microtubules and relocates the AIS, which in 
turn depolarizes the threshold for AP initiation, reducing AP ampli-
tude and AP firing
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manner via the activation of L- and/or T-type calcium chan-
nels and subsequent downstream signaling that requires the 
calcium-activated phosphatase calcineurin [8, 16]. The data 
presented here indicate that relocation of the AIS requires 
structural changes to the microtubule network, a finding 
supported by a recent analysis of microtubules in the AIS 
[46]. Given that microtubules are modulated by patho-
logical tau phosphorylation, it is possible that, under nor-
mal conditions, physiological tau phosphorylation plays a 
role in modulating the AIS, although this requires further 
investigation.
Acknowledgements We thank Professor Pankaj Sah for use of 
experimental equipment and space, Professor Stephen R Williams, 
Ms Rowan Tweedale and Dr Alan Woodruff for critically reading 
of the manuscript, and Professor Karen Ashe for the deposition of 
plasmids to Addgene. This work was supported by the Estate of Dr 
Clem Jones AO and by grants from the Australian Research Council 
[DP130101932], the National Health and Medical Research Council 
of Australia [APP1037746, APP1003150], the IBP-QBI collabora-
tion grant ([CAS-20140909] and Queensland-Chinese Academy of 
Science Biotechnology Fund [GJHZ1131, GJHZ201302]), and the 
Australian Research Council Linkage Infrastructure, Equipment and 
Facilities scheme [LE100100074].
Compliance with ethical standards 
Conflict of interest None of the authors has any conflict of interest to 
disclose. We confirm that we have read the Journal’s position on issues 
involved in ethical publication and affirm that this report is consistent 
with those guidelines.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Ballatore C, Lee VMY, Trojanowski JQ (2007) Tau-mediated 
neurodegeneration in Alzheimer’s disease and related disorders. 
Nat Rev Neurosci 8:663–672. doi:10.1038/nrn2194
 2. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, 
Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosen-
berry TL, Lewis J, Hutton M, Janus C (2007) Accumulation 
of pathological tau species and memory loss in a conditional 
model of tauopathy. J Neurosci 27:3650–3662. doi:10.1523/
jneurosci.0587-07.2007
 3. Crimins JL, Rocher AB, Luebke JI (2012) Electrophysiologi-
cal changes precede morphological changes to frontal cortical 
pyramidal neurons in the rTg4510 mouse model of progressive 
tauopathy. Acta Neuropathol 124:777–795
 4. Crimins JL, Rocher AB, Peters A, Shultz P, Lewis J, Luebke 
JI (2011) Homeostatic responses by surviving cortical pyrami-
dal cells in neurodegenerative tauopathy. Acta Neuropathol 
122:551–564
 5. Dalby NO, Volbracht C, Helboe L, Larsen PH, Jensen HS, Ege-
bjerg J, Elvang AB (2014) Altered function of hippocampal CA1 
pyramidal neurons in the rTg4510 mouse model of tauopathy. J 
Alzheimers Dis 40:429–442. doi:10.3233/JAD-131358
 6. Deters N, Ittner LM, Götz J (2008) Divergent phosphorylation 
pattern of tau in P301L tau transgenic mice. Eur J Neurosci 
28:137–147. doi:10.1111/j.1460-9568.2008.06318.x
 7. DeVos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada 
K, Stewart FR, Schuler DR, Maloney SE, Wozniak DF, Rigo F, 
Bennett CF, Cirrito JR, Holtzman DM, Miller TM (2013) Anti-
sense reduction of tau in adult mice protects against seizures. J 
Neurosci 33:12887–12897
 8. Evans MD, Sammons RP, Lebron S, Dumitrescu AS, Watkins 
TBK, Uebele VN, Renger JJ, Grubb MS (2013) Calcineu-
rin signaling mediates activity-dependent relocation of the 
axon initial segment. J Neurosci 33:6950–6963. doi:10.1523/
jneurosci.0277-13.2013
 9. Fath T, Ke YD, Gunning P, Götz J, Ittner LM (2009) Primary 
support cultures of hippocampal and substantia nigra neurons. 
Nat Protoc 4:78–85. doi:10.1038/nprot.2008.199
 10. Fleidervish IA, Lasser-Ross N, Gutnick MJ, Ross WN (2010) 
Na+ imaging reveals little difference in action potential-evoked 
Na+ influx between axon and soma. Nat Neurosci 13:852–860. 
doi:10.1038/nn.2574
 11. Galarreta M, Hestrin S (1999) A network of fast-spiking cells in 
the neocortex connected by electrical synapses. Nature 402:72–
75. doi:10.1038/47029
 12. Goedert M, Jakes R (2005) Mutations causing neurodegen-
erative tauopathies. Biochim Biophys Acta 1739:240–250. 
doi:10.1016/j.bbadis.2004.08.007
 13. Götz J, Chen F, Barmettler R, Nitsch RM (2001) Tau filament 
formation in transgenic mice expressing P301L tau. J Biol Chem 
276:529–534. doi:10.1074/jbc.M006531200
 14. Götz J, Chen F, van Dorpe J, Nitsch RM (2001) Forma-
tion of neurofibrillary tangles in P301L tau transgenic mice 
induced by Aβ42 fibrils. Science 293:1491–1495. doi:10.1126/
science.1062097
 15. Götz J, Ittner LM (2008) Animal models of Alzheimer’s disease 
and frontotemporal dementia. Nat Rev Neurosci 9:532–544. 
doi:10.1038/nrn2420
 16. Grubb MS, Burrone J (2010) Activity-dependent relocation of 
the axon initial segment fine-tunes neuronal excitability. Nature 
465:1070–1074. doi:10.1038/nature09160
 17. Hamada MS, Kole MHP (2015) Myelin loss and axonal ion 
channel adaptations associated with gray matter neuronal hyper-
excitability. J Neurosci 35:7272–7286
 18. Hatch RJ, Reid CA, Petrou S (2015) Generation of Local CA1 
γ oscillations by tetanic stimulation. J Vis Exp e52877–e52877. 
doi:10.3791/52877
 19. Hinman JD, Rasband MN, Carmichael ST (2013) Remodeling 
of the axon initial segment after focal cortical and white matter 
stroke. Stroke 44:182–189
 20. Holth JK, Bomben VC, Reed JG, Inoue T, Younkin L, Younkin 
SG, Pautler RG, Botas J, Noebels JL (2013) Tau loss attenuates 
neuronal network hyperexcitability in mouse and Drosophila 
genetic models of epilepsy. J Neurosci 33:1651–1659
 21. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant 
MK, Pitstick R, Carlson GA, Lanier LM, Yuan L-L, Ashe KH, 
Liao D (2010) Tau mislocalization to dendritic spines mediates 
synaptic dysfunction independently of neurodegeneration. Neu-
ron 68:1067–1081. doi:10.1016/j.neuron.2010.11.030
 22. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL (1984) 
Alzheimer’s disease: cell-specific pathology isolates the hip-




 23. Iqbal K, Liu F, Gong C-X (2016) Tau and neurodegenerative 
disease: the story so far. Nat Rev Neurol 12:15–27. doi:10.1038/
nrneurol.2015.225
 24. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel 
J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, 
Staufenbiel M, Hardeman E, Götz J (2010) Dendritic function 
of tau mediates amyloid-β toxicity in Alzheimer’s disease mouse 
models. Cell 142:387–397. doi:10.1016/j.cell.2010.06.036
 25. Jenkins SM, Bennett V (2001) Ankyrin-G coordinates assembly 
of the spectrin-based membrane skeleton, voltage-gated sodium 
channels, and L1 CAMs at Purkinje neuron initial segments. J 
Cell Biol 155:739–746. doi:10.1083/jcb.200109026
 26. Jones SL, Korobova F, Svitkina T (2014) Axon initial segment 
cytoskeleton comprises a multiprotein submembranous coat con-
taining sparse actin filaments. J Cell Biol 205:67–81
 27. Kawaguchi Y, Kubota Y (1993) Correlation of physiologi-
cal subgroupings of nonpyramidal cells with parvalbumin- 
and calbindinD28k-immunoreactive neurons in layer V of 
rat frontal cortex. J Neurophysiol 70:387–396. doi:10.1016/
S0306-4522(97)00685-4
 28. Kole MHP, Ilschner SU, Kampa BM, Williams SR, Ruben PC, 
Stuart GJ (2008) Action potential generation requires a high 
sodium channel density in the axon initial segment. Nat Neurosci 
11:178–186. doi:10.1038/nn2040
 29. Kopeikina KJ, Wegmann S, Pitstick R, Carlson GA, Bacskai BJ, 
Betensky RA, Hyman BT, Spires-Jones TL (2013) Tau causes 
synapse loss without disrupting calcium homeostasis in the 
rTg4510 model of tauopathy. PLoS One 8:e80834. doi:10.1371/
journal.pone.0080834
 30. Kuba H, Oichi Y, Ohmori H (2010) Presynaptic activity regulates 
Na(+) channel distribution at the axon initial segment. Nature 
465:1075–1078
 31. Kuchibhotla KV, Wegmann S, Kopeikina KJ, Hawkes J, Rudins-
kiy N, Andermann ML, Spires-Jones TL, Bacskai BJ, Hyman BT 
(2014) Neurofibrillary tangle-bearing neurons are functionally 
integrated in cortical circuits in vivo. Proc Natl Acad Sci USA 
111:510–514. doi:10.1073/pnas.1318807111
 32. Leterrier C, Vacher H, Fache M-P, d’Ortoli SA, Castets F, 
Autillo-Touati A, Dargent B (2011) End-binding proteins EB3 
and EB1 link microtubules to ankyrin G in the axon initial seg-
ment. Proc Natl Acad Sci USA 108:8826–8831
 33. Li X, Kumar Y, Zempel H, Mandelkow E-M, Biernat J, Man-
delkow E (2011) Novel diffusion barrier for axonal retention of 
Tau in neurons and its failure in neurodegeneration. EMBO J 
30:4825–4837. doi:10.1038/emboj.2011.376
 34. Madison DV, Nicoll RA (1984) Control of the repetitive dis-
charge of rat CA1 pyramidal neurones in vitro. J Physiol (Lond) 
354:319–331. doi:10.1111/(ISSN)1469-7793
 35. Matamales M, Skrbis Z, Hatch RJ, Balleine BW, Götz J, Ber-
tran-Gonzalez J (2016) Aging-related dysfunction of striatal cho-
linergic interneurons produces conflict in action selection. Neu-
ron 90:362–373. doi:10.1016/j.neuron.2016.03.006
 36. Menkes-Caspi N, Yamin HG, Kellner V, Spires-Jones TL, Cohen 
D, Stern EA (2015) Pathological tau disrupts ongoing network 
activity. Neuron 85:959–966. doi:10.1016/j.neuron.2015.01.025
 37. Mustroph ML, King MA, Klein RL, Ramirez JJ (2012) Adult-
onset focal expression of mutated human tau in the hippocam-
pus impairs spatial working memory of rats. Behav Brain Res 
233:141–148. doi:10.1016/j.bbr.2012.04.034
 38. Palay SL, Sotelo C, Peters A, Orkand PM (1968) The axon hill-
ock and the initial segment. J Cell Biol 38:193–201
 39. Palmer LM, Stuart GJ (2006) Site of action potential initia-
tion in layer 5 pyramidal neurons. J Neurosci 26:1854–1863. 
doi:10.1523/jneurosci.4812-05.2006
 40. Polydoro M, Acker CM, Duff K, Castillo PE, Davies P 
(2009) Age-dependent impairment of cognitive and synaptic 
function in the htau mouse model of tau pathology. J Neurosci 
29:10741–10749
 41. Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, 
SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton 
M, Ashe KH (2005) Age-dependent neurofibrillary tangle for-
mation, neuron loss, and memory impairment in a mouse model 
of human tauopathy (P301L). J Neurosci 25:10637–10647. 
doi:10.1523/jneurosci.3279-05.2005
 42. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu 
T, Gerstein H, Yu G-Q, Mucke L (2007) Reducing endogenous 
tau ameliorates amyloid beta-induced deficits in an Alzheimer’s 
disease mouse model. Science 316:750–754
 43. Rocher AB, Crimins JL, Amatrudo JM, Kinson MS, Todd-
Brown MA, Lewis J, Luebke JI (2010) Structural and functional 
changes in tau mutant mice neurons are not linked to the pres-
ence of NFTs. Exp Neurol 223:385–393
 44. Royeck M, Horstmann M-T, Remy S, Reitze M, Yaari Y, Beck 
H (2008) Role of axonal NaV1.6 sodium channels in action 
potential initiation of CA1 pyramidal neurons. J Neurophysiol 
100:2361–2380. doi:10.1152/jn.90332.2008
 45. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson 
M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster 
C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, 
Hutton M, Ashe KH (2005) Tau suppression in a neurodegenera-
tive mouse model improves memory function. Science 309:476–
481. doi:10.1126/science.1113694
 46. Sohn PD, Tracy TE, Son H-I, Zhou Y, Leite REP, Miller BL, 
Seeley WW, Grinberg LT, Gan L (2016) Acetylated tau destabi-
lizes the cytoskeleton in the axon initial segment and is mislo-
calized to the somatodendritic compartment. Mol Neurodegener 
2016 11(1):47. doi:10.1186/s13024-016-0109-0
 47. Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC 
(1996) Regulation of the phosphorylation state and microtubule-
binding activity of Tau by protein phosphatase 2A. Neuron 
17:1201–1207. doi:10.1016/S0896-6273(00)80250-0
 48. Staff NP, Jung HY, Thiagarajan T, Yao M, Spruston N (2000) 
Resting and active properties of pyramidal neurons in subiculum 
and CA1 of rat hippocampus. J Neurophysiol 84:2398–2408
 49. Tamás G, Szabadics J, Lorincz A, Somogyi P (2004) Input and 
frequency-specific entrainment of postsynaptic firing by IPSPs 
of perisomatic or dendritic origin. Eur J Neurosci 20:2681–2690. 
doi:10.1111/j.1460-9568.2004.03719.x
 50. van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, Götz J, Ittner LM 
(2010) Sodium selenate mitigates tau pathology, neurodegenera-
tion, and functional deficits in Alzheimer’s disease models. Proc 
Natl Acad Sci USA 107:13888–13893
 51. Xia D, Gutmann JM, Götz J (2016) Mobility and subcellular 
localization of endogenous, gene-edited Tau differs from that of 
over-expressed human wild-type and P301L mutant Tau. Sci Rep 
6:29074. doi:10.1038/srep29074
 52. Xia D, Li C, Götz J (2015) Pseudophosphorylation of Tau at dis-
tinct epitopes or the presence of the P301L mutation targets the 
microtubule-associated protein Tau to dendritic spines. Biochim 
Biophys Acta 1852:913–924. doi:10.1016/j.bbadis.2014.12.017
 53. Yang Y, Ogawa Y, Hedstrom KL, Rasband MN (2007) βIV spec-
trin is recruited to axon initial segments and nodes of Ranvier by 
ankyrinG. J Cell Biol 176:509–519. doi:10.1083/jcb.200610128
 54. Zhong G, He J, Zhou R, Lorenzo D, Babcock HP, Bennett V, 
Zhuang X (2014) Developmental mechanism of the periodic 
membrane skeleton in axons. Elife 3:e04581
 55. Zhou D, Lambert S, Malen PL, Carpenter S, Boland LM, Bennett 
V (1998) AnkyrinG is required for clustering of voltage-gated Na 
channels at axon initial segments and for normal action potential 
firing. J Cell Biol 143:1295–1304. doi:10.1083/jcb.143.5.1295
